-
CTH 2025 | Prof. Defu Zeng: Pathogenesis and Therapeutic Advances in Chronic Graft-Versus-Host Disease
Oncology Frontier-Hematology Frontier：In your research, what new cellular and molecular mechanisms of chronic graft-versus-host disease (cGVHD) have been identified? Compared with previous understandings, what major breakthroughs do these new findings…
-
Five-Year CheckMate 649 Update: Nivolumab Plus Chemo Extends Survival for Chinese Gastric Cancer Patients
Introduction Gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma are among the most aggressive malignancies, particularly in their advanced stages. The CheckMate 649 trial previously established nivolumab plus chemotherapy as a superior first-line treatment compared to chemotherapy alone. With five years of follow-up, this latest analysis provides crucial insights into long-term survival, disease progression, and…
-
MAINTAIN Trial: Shaping Post-CDK4/6i Strategies in HR+/HER2− Metastatic Breast Cancer
Although published in 2023, the MAINTAIN trial remains a key reference in the evolving management of HR+/HER2− metastatic breast cancer following progression on CDK4/6 inhibitors.In this randomized, placebo-controlled phase II…
-
ESMO China Voice | Dr. Cheng Huang & Dr. Rongbo Lin: Global First Evidence Shows IV IPCA Outperforms Oral Morphine for Severe Cancer Pain, Potentially Changing Guidelines and Transforming Pain Management
The 2024 European Society for Medical Oncology (ESMO) Annual Meeting was held in Barcelona, Spain. A Phase III randomized controlled trial (SYLT-021), led by Dr. Rongbo Lin’s team from the Department of Gastrointestinal Oncology, Fujian Cancer Hospital, was selected as one of six Proffered Paper oral presentations in the palliative care session. This study compared…
-
Addressing Hemorrhagic Cystitis in HCT: Insights from Dr. Simone Cesaro on BK Virus Surveillance and Clinical Practice Gaps
In this exclusive interview with Infectious Diseases Frontier, Professor Simone Cesaro, a leading expert in pediatric hematology and stem cell transplantation, shares his perspectives on the management of BK polyomavirus-associated hemorrhagic cystitis (HC) following hematopoietic cell transplantation (HCT). Drawing from the findings of a recent EBMT survey, he discusses the clinical implications of passive surveillance…
-
EBMT 2025: Opening Ceremony Celebrates Legacy, Innovation, and a Unified Vision for the Future of Transplantation
Florence, Italy — March 30, 2025 – The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) commenced in Florence with a compelling and multifaceted opening ceremony that captured the essence of what the EBMT represents. Far beyond a traditional welcome, the evening unfolded as a rich tapestry of scientific achievement,…
-
Celebrating Excellence at EBMT 2025: Award Highlights from Florence
Best Essay Awards: Thought Leadership Through the “Five Best Essays” In a session both engaging and reflective, five finalists presented their original essays tackling some of the most pressing and…
Connecting Medical Expertise through Media
